Phase 2 Study of VGT-309 in Lung Cancer
NCT05400226
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
40
Enrollment
INDUSTRY
Sponsor class
Conditions
Lung Cancer
Interventions
DRUG:
VGT-309
Sponsor
Vergent Bioscience, Inc.
Collaborators
[object Object]